AMC opens up CAR T-Cell therapy center in Seoul

Share This Post

Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah’s CAR-T cell therapy.

AMC announced on Tuesday that its cancer hospital had opened a CAR-T facility and had started paying for Kymriah treatments that had been approved by Novartis.

Asan medical center seoul korea

In CAR-T therapy, immune cells (T cells) from the patient are removed and transfected with chimeric antigen receptors that target particular cancer cells. The patient is then given an injection of T cells to eradicate the cancer cells.

When treating patients with relapsed and refractory B-cell acute lymphoblastic leukaemia (ALL) who are 25 years of age or younger as well as individuals with refractory diffuse large B-cell lymphoma, Kymriah is covered by insurance (DLBCL).

Relapsed and refractory B-cell ALL and relapsed and refractory DLBCL have been extremely challenging to treat thus far, with the majority of these patients barely living for six months following diagnosis.

According to statistics, CAR-T treatment kills cancer in 50% of adult patients with relapsed and refractory DLBCL and roughly 80% of paediatric patients with relapsed and refractory B-cell ALL.

 

Professor Ho Joon Im CAR T Cell therapy specialist in South Korea

Image: Baby Lee receiving a small Christmas present from Professor Ho Joon Im (Courtsey: Asan medical Center website)

Only adult patients will be seen at the AMC’s CAR-T facility by the oncologists Yoon Dok-hyun, Cho Hyung-woo, and the haematologists Lee Jung-hee and Park Han-seung.

Im Ho-joon, Koh Kyung-nam, Kim Hye-ry, and Kang Sung-han, paediatric hemato-oncologists, will provide care for young patients.

Yoon Dok-hyun, the director of the AMC’s CAR-T centre, stated that although CAR-T therapy has a very dramatic effect, it may also result in negative side effects. The first interdisciplinary clinic for CAR-T treatment has been developed by AMC’s CAR-T centre in collaboration with numerous departments, including intensive care unit, neurology, and infectious disease, to build protocols to detect side effects early and provide safe treatment.

 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy